Flow description of the results of the treatment program (ALL MRD2014 study). A total of 164 adult patients with ALL were enrolled in this study between January 2014 and December 2019. Of the 164 patients enrolled, 61 were excluded from the study because of Ph positivity and 5 due to misdiagnosis. The remaining 98 patients were Ph^–; among them, MRD could be evaluated in 81 patients. We used a modified CALGB 19802 treatment protocol that comprised 6 courses of chemotherapy administered in the order of A-B-C-A-B-C regimens, followed by a maintenance phase. MRD status was assessed in our study at 2 critical points: first, after the induction therapy (first course A1), denoted as the EOI; and second, after the second consolidation therapy (first course C), referred to as the EOC. EOC MRD-positive patients were considered to be indicated for allogeneic hematopoietic stem cell transplantation (HSCT) as soon as possible. BM, bone marrow; CNS, central nervous system; EM, extramedullary.